We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
During clinical development, biosimilars makers can request as many meetings with FDA reviewers as necessary but they need to be outcomes-based with a priority on narrowly defined questions that the FDA can answer. Read More
Drugmakers engaging in anticompetitive practices don’t get a free pass simply because federal regulators failed to act, the Federal Trade Commission has asserted in a pending court case. Read More
The majority of the Senate Committee on Health, Education, Labor and Pensions, from both sides of the aisle, supported Robert Califf’s nomination as the next FDA commissioner during a two-hour confirmation hearing Nov. 17. Read More
Biosimilars experts concluded that fostering the nascent industry would require many of the same elements that originally nurtured the generics industry: educational efforts, regulatory and patent changes, and most importantly, patience. Read More
Two high-profile drugmakers have entered settlement agreements with federal and state justice departments over kickback allegations for prescribing practices. Read More
The U.S. Treasury Department says it is taking steps to curb tax-avoiding inversion deals, but there is little evidence to suggest it will halt the tie-up between New York-based Pfizer and Allergan that will see the former move its headquarters to Dublin. Read More
Drugmakers engaging in anticompetitive practices don’t get a free pass simply because federal regulators failed to act, the Federal Trade Commission has asserted in a pending court case. Read More
Spotty, inconclusive data and potentially skewed, biased findings have raised FDA concerns about the efficacy of BioMarin Pharmaceutical’s Duchenne muscular dystrophy candidate drisapersen, which is scheduled to go before members of an agency advisory panel tomorrow. Read More
The FDA has given Takeda’s Ninlaro the green light of approval in combination with other therapies to treat multiple myeloma in the second-line setting. Read More